These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34759344)

  • 1. Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
    Zhang B; Zhang M; Yang Y; Li Q; Yu J; Zhu S; Niu Y; Shang Z
    Oncogene; 2022 Jan; 41(3):387-399. PubMed ID: 34759344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance.
    Zhang B; Zhang M; Shen C; Liu G; Zhang F; Hou J; Yao W
    Cell Death Dis; 2021 Sep; 12(10):856. PubMed ID: 34545063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
    Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
    Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
    Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
    Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Long Noncoding RNA
    Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP
    Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
    Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
    Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy.
    Cui SZ; Lei ZY; Guan TP; Fan LL; Li YQ; Geng XY; Fu DX; Jiang HW; Xu SH
    Cancer Sci; 2020 May; 111(5):1567-1581. PubMed ID: 32133742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells.
    Gupta S; Pungsrinont T; Ženata O; Neubert L; Vrzal R; Baniahmad A
    Horm Cancer; 2020 Aug; 11(3-4):182-190. PubMed ID: 32562083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.
    McKay RR; Kwak L; Crowdis JP; Sperger JM; Zhao SG; Xie W; Werner L; Lis RT; Zhang Z; Wei XX; Lang JM; Van Allen EM; Bhatt RS; Yu EY; Nelson PS; Bubley GJ; Montgomery RB; Taplin ME
    Clin Cancer Res; 2021 Jul; 27(13):3610-3619. PubMed ID: 33849963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
    Kohrt SE; Awadallah WN; Phillips RA; Case TC; Jin R; Nanda JS; Yu X; Clark PE; Yi Y; Matusik RJ; Anderson PD; Grabowska MM
    Mol Cancer Ther; 2021 Feb; 20(2):398-409. PubMed ID: 33298586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
    Li J; Hong Z; Zhang J; Zheng S; Wan F; Liu Z; Dai B
    Oncogene; 2024 Mar; 43(10):744-757. PubMed ID: 38243079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.
    Liu JS; Fang WK; Yang SM; Wu MC; Chen TJ; Chen CM; Lin TY; Liu KL; Wu CM; Chen YC; Chuu CP; Wang LY; Hsieh HP; Kung HJ; Wang WC
    J Biomed Sci; 2022 May; 29(1):29. PubMed ID: 35534851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective degradation of AR-V7 to overcome castration resistance of prostate cancer.
    Liu Y; Yu C; Shao Z; Xia X; Hu T; Kong W; He X; Sun W; Deng Y; Liao Y; Huang H
    Cell Death Dis; 2021 Sep; 12(10):857. PubMed ID: 34548474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
    Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
    Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of ATP Binding Cassette Subfamily C Member 5 facilitates Prostate Cancer progression and Enzalutamide resistance via the CDK1-mediated AR Ser81 Phosphorylation Pathway.
    Ji G; He S; Huang C; Gong Y; Li X; Zhou L
    Int J Biol Sci; 2021; 17(7):1613-1628. PubMed ID: 33994848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Sun W; Li L; Du Z; Quan Z; Yuan M; Cheng H; Gao Y; Luo C; Wu X
    Oncol Rep; 2019 May; 41(5):2689-2702. PubMed ID: 30864728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L; Schweizer MT
    Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer.
    Farah E; Zhang Z; Utturkar SM; Liu J; Ratliff TL; Liu X
    Mol Cancer Ther; 2022 Jan; 21(1):193-205. PubMed ID: 34728570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.